Overview

• Cibus Q3 revenue misses analyst expectations, reporting $615,000 compared to $1.39 mln estimate

• Net loss for Q3 was $24.3 mln, significantly lower than $201.5 mln last year

• Company focuses on strategic partnerships and cost reductions to support future growth

Outlook

• Cibus targets initial commercial launch of rice traits in Latin America by 2027

• Company plans commercial expansion of Sustainable Ingredients program in 2026

• Cibus aims to reduce annual net cash usage to $30 mln by 2026

Result Drivers

• LATAM EXPANSION - Cibus continues to progress with herbicide tolerance traits in Rice, targeting initial commercial launches in Latin America by 2027

• INDIA MARKET ENTRY - Cibus engaged AgVayā to support entry into Indian market for advanced gene editing solutions

• BIOFRAGRANCE PILOT - Successfully completed pre-commercial pilot runs for biofragrance products, targeting commercial expansion in 2026

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Cibus Inc is $15.50, about 91.3% above its November 12 closing price of $1.35

Press Release: ID:nGNX3yN8qv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)